The transaction, recorded on the 17th of February, 2026 – a date which, I suspect, will be remembered for reasons other than meteorological phenomena – represents a significant 6.44% allocation of Great Point’s 13F assets. A rather bold wager, wouldn’t you agree? One pictures the portfolio manager, a man named, let us say, Mr. Finch, peering into the abyss of clinical trial data and declaring, with a flourish, “All in!”
The question isn’t simply why this has happened, but whether it will endure. The markets are fickle, prone to sudden enthusiasms and equally swift disillusionments. But beneath the surface of quarterly reports and stock tickers, there’s a deeper current at work, a return to the fundamentals of value and necessity.
Enter Eli Lilly (LLY 1.43%), bearing not merely a remedy, but a veritable siege upon the market. With tirzepatide, christened Mounjaro and then Zepbound, they have not simply entered the fray, but seized a commanding share – a full sixty percent of this burgeoning American appetite for alteration. One observes, with a touch of amusement, the swiftness with which fortunes shift in this realm of waistlines and wallets.
The stock took a tumble, naturally. Down 32% in a year? That’s less “home appliance giant” and more “slightly used toaster oven.” Tepper’s Appaloosa Management had a stake, then…trimmed it. It’s the corporate equivalent of ghosting. They still have a little skin in the game, though. Like, they’re still on Facebook with the ex, just mostly lurking.
Despite this modest setback, the accounts remain, shall we say, presentable. Revenue for 2025 reached $72.2 billion – a perfectly respectable sum. Earnings per share, a figure increasingly divorced from reality, reached $15.38. A tidy profit, even after discounting the rather convenient windfall from the disposal of Accertify. One suspects the accountants are quite pleased.
They’re calling it a ‘position increase.’ I call it throwing good money after… well, let’s just say ‘potential.’ It now represents 1.96% of their portfolio. Which, if you’re keeping track – and honestly, who isn’t – means they’re still mostly betting on SEMrush. Smart. SEMrush is predictable. Sportradar? It’s a bit of a wild card. A shiny, data-filled wild card.
They keep talking about Vera Rubin, Nvidia’s new chip. Supposedly, it’s going to solve all our problems. Reduce costs, improve performance… It’s always the same promises. Meanwhile, they’re trading at 24 times sales. Twenty-four. It’s insulting. Like they expect a reward just for existing. And people are buying it! It’s like a collective delusion.
The company itself reports revenues dwindling, losses deepening – a perfectly respectable trajectory for a concern navigating the treacherous currents of modern commerce. But this, it seems, was anticipated. Management, in a display of what one might charitably call ‘strategic repositioning,’ is abandoning its traditional markets, like a ship shedding ballast before entering a storm, and setting sail for the shimmering, yet ultimately elusive, promise of high-power AI data centers. One pictures frantic carpenters rebuilding the vessel mid-voyage, using whatever materials come to hand.
Now, IonQ… they’ve had a run. 550% over three years! Oy vey! That’s… something. But let’s not confuse a flash in the pan with a solid investment. This ain’t the stock market; it’s a vaudeville show! They’re losin’ money faster than I lose my patience with slow walkers, and quantum computin’ itself is still years away from actually makin’ a buck. Years! That’s an eternity in the stock market. It’s like waitin’ for Godot, but with more silicon.
By noon ET, the Nasdaq Composite (^IXIC +1.13%) was leading the charge, closely followed by the S&P 500 (^GSPC +0.73%). The Dow Jones Industrial Average (^DJI +0.59%)? Well, let’s just say it was bringing up the rear, but still technically moving forward. Progress, people! It’s a concept.